FDA approves new non-opioid medication for moderate to severe pain

Even where cannabis is legal, product safety isn't guaranteed

Generations flip the script on alcohol

How do Mexico, Canada, and China affect fentanyl flowing into the U.S.?

A secure base: Harm reduction as attachment therapy

Inside the DEA's Chicago drug testing lab

Editorial: Beyond buprenorphine in the ED: Leveraging lessons from 10 years of implementation

Denver proposes licensing rules for psychedelic centers

Opioid use disorder in sexually and gender diverse populations: Can we do better?

NEW PAPERS AND REPORTS

 FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain (FDA, February 5, 2025)

Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose (Nature Communications, February 6, 2025)

Changes in Incident Schizophrenia Diagnoses Associated With Cannabis Use Disorder After Cannabis Legalization (Free pdf. JAMA Network Open, February 5, 2025)

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl (Free pdf download. JAMA Network Open, January 25, 2025)

mHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder (Addiction Science and Clinical Practice, January 30, 2025)

Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose (Nature Communications, February 6, 2025)

Find more research here